HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Kicks Off Asia PIII for Mirogabalin
March 28, 2019
- Chugai’s SMA Drug Risdiplam Gets Orphan Status
March 28, 2019
- JSR Enters Strategic Partnership with Dutch Institute in Oncology Field
March 28, 2019
- Astellas’ Vasomotor Symptom Treatment Fezolinetant Smashes Primary Goals in US PIIb Study
March 28, 2019
- Kymriah OK’ed, Novartis Says It’s Not Up for Outcome-Based Pricing in Japan
March 27, 2019
- AnGes Bags Conditional Approval for Collategene Gene Therapy
March 27, 2019
- Fujifilm, NCC Join Hands for I/O Research, Combining Liposomes with Immune Checkpoint Inhibitors
March 27, 2019
- Boehringer’s Ofev Gets Orphan Status for ILD in Systemic Sclerosis
March 27, 2019
- Novartis Snags Japan Approval for CAR-T Therapy Kymriah
March 26, 2019
- Novartis to Tap Disease Registry for Kymriah’s All-Case PMS: Exec
March 26, 2019
- SanBio to Move Ahead with SB623 Development in Stroke after PII Miss: President
March 26, 2019
- Avanir’s Alzheimer’s Agitation Drug Hits Primary Goal in PIII
March 26, 2019
- AstraZeneca Grabs All Global Fasenra Rights in Expanded Pact with Kyowa Kirin
March 26, 2019
- Vimpat IV Version Hits Japan Market: UCB, Daiichi Sankyo
March 26, 2019
- Ono Chief Recounts Long and Winding Road of Opdivo Development, Thanks Kyoto Univ. Professor
March 25, 2019
- JCR Files Temcell for Epidermolysis Bullosa
March 25, 2019
- Japan Biosimilar Market Could Grow Like in Europe If Incentives Improved: Sandoz Japan Chief
March 25, 2019
- Eisai Going Ahead with Global PIII for BAN2401 despite Aducanumab Setback
March 25, 2019
- Analyst Says Drug Makers Can’t Recoup Investment in Overcompetitive Oncology Arena
March 22, 2019
- Biogen/Eisai’s Aducanumab Fails, Dashing Hopes in Alzheimer’s Field
March 22, 2019
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
